Evidence map›Paper›PMID 10565831›Full record

ArticleThe Journal of pharmacology and experimental therapeutics1999

Intracisternal nor-binaltorphimine distinguishes central and peripheral kappa-opioid antinociception in rhesus monkeys.

M C Ko, M D Johnson, E R Butelman, K J Willmont, H I Mosberg, J H Woods

Open access · greenAbstract read
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
0.3field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Article
  3. Opioid Analgesia and Opioid-Induced Adverse Effects: A Review.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  4. Article
  5. Review
  6. Article
  7. Effects of NOP-Related Ligands in Nonhuman Primates.Handbook of experimental pharmacology · 2019
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

M C KoDepartment of Pharmacology, Medical School, The University of Michigan, Ann Arbor, Michigan 48109-0632, USA. mko@umich.edu
M D Johnson
E R Butelman
K J Willmont
H I Mosberg
J H Woods
University of Michigan–Ann Arbor · USRockefeller University · US

Funding

Selective radiolabeled agonists /antagonists for opiate receptor subtypesP50DA000254 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI JOHANSON, CHRIS-ELLYN · 1985 to 2002
$5.0M
Narcotic Drug and Opioid Peptide Basic Research projectP01DA000254 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WOODS, JAMES H · 2003 to 2006
$5.0M
COGNITIVE INTERVENTION FOR DRUG ABUSING ADOLESCENTSK21DA000254 · NIDA · UNIVERSITY OF MINNESOTA TWIN CITIES · PI LATIMER, WILLIAM W · 1995 to 1999
–
NIDA NIH HHS DA00254NIDA NIH HHS K21 DA000254NIDA NIH HHS P01 DA000254NIDA NIH HHS P50 DA000254
6 · The paper itself

Abstract

Systemic administration of nor-binaltorphimine (nor-BNI) produces a long-lasting kappa-opioid receptor (kappaOR) antagonism and has kappa(1)-selectivity in nonhuman primates. The aim of this study was to establish the pharmacological basis of central kappaOR antagonism in rhesus monkeys (Macaca mulatta). After intracisternal (i.c.) administration of small doses of nor-BNI, the duration and selectivity of nor-BNI antagonism were evaluated against two kappaOR agonists, (trans)-3, 4-dichloro-N-methyl-N-[2-(1-pyrrolidinyl)-cyclohexyl]benzeneacetamide (U50,488) and bremazocine. Thermal antinociception was measured in the warm water (50 degrees C) tail-withdrawal assay and sedation was evaluated by observers blind to treatment conditions. Following i.c. pretreatment with 0.32 mg nor-BNI, a 5- to 10-fold rightward shift of the U50,488 baseline dose-effect curve was observed in antinociception. In contrast, this dose of nor-BNI only produced an insignificant 2-fold shift against bremazocine. Pretreatment with a smaller dose (0.032 mg) of nor-BNI produced a 3-fold shift of U50, 488, which lasted for 7 days, but failed to alter the potency of bremazocine. This differential antagonism profile of i.c. nor-BNI also was observed in sedation ratings. In addition, the centrally effective dose of nor-BNI (0.32 mg), when administered s.c. in the back, did not antagonize either U50,488- or bremazocine-induced antinociception and sedation. After i.c. pretreatment with the same dose, nor-BNI also did not antagonize the peripherally mediated effect of U50,488 against capsaicin-induced thermal nociception in the tail. These results indicate that i.c. nor-BNI produces central kappaOR antagonism and support the notion of two functional kappaOR subtypes in the central nervous system. Moreover, it provides a valuable pharmacological basis for further characterizing different sources of kappaOR-mediated effects, namely, from central or peripheral nervous system receptors.

Indexed as

3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerAnalgesicsAnalgesics, OpioidAnimalsBenzomorphansCentral Nervous SystemCisterna MagnaDose-Response Relationship, DrugFemaleHot TemperatureInjectionsMacaca mulattaMaleNaltrexoneNarcotic AntagonistsPeripheral Nervous System3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-IsomerAnalgesicsAnalgesics, OpioidBenzomorphansbremazocineNaltrexoneNarcotic AntagonistsnorbinaltorphimineReceptors, Opioid, kappa

Identifiers

PMID10565831
PMCPMC2939326
OpenAlexW1892654623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.